Share

Abbott Laboratories (ABT.NYSE) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 20 September 2026Deep analysis 20 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

SynthesizerCombines all advisor views

Synthesis of 14 independent opinions

Diversity of ModelsSame approach, varied models

Diversity of FrameworksDifferent investing styles

AI Researcher

Opus 5

Universal Investor AI

The Polymath Framework

Model rating

Buy

5-Year Return Est.

+61.2%

Includes 1.71% annual net dividend contribution

1. Investment Thesis — Base Case

The central tension is a quality franchise wearing a cyclical's price tag. Abbott's reported numbers are distorted in both directions - flattered on revenue by Exact Sciences, punished on GAAP earnings by the debt and amortisation that bought it. Beneath the distortion sits mid-single-digit organic growth, an improving 58% adjusted gross margin and $8.72bn of trailing free cash flow. Over five years the dilution laps, leverage normalises toward 2x, the NEC docket clears in stages, and the multiple drifts back toward its historical band. The result is compounding earnings plus partial multiple repair, not a violent re-rating.

Guided FY2026 adjusted of $5.45-$5.60 puts $103 near 18.5x forward, the low end of the decade band [1].
Assume roughly 7% adjusted EPS growth to about $8.00 by 2031; a 19x exit implies approximately $152 per share.
Trailing of $8.72bn covers the $2.52 annualised dividend nearly twice while funding steady deleveraging.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-09-16	127
Observed price	2021-10-04	116
Observed price	2021-10-17	117
Observed price	2021-10-30	129
Observed price	2021-11-16	130
Observed price	2021-11-25	125
Observed price	2021-12-03	131
Observed price	2021-12-25	140
Observed price	2021-12-29	141
Observed price	2022-01-20	126
Observed price	2022-01-24	121
Observed price	2022-02-02	130
Observed price	2022-02-24	121
Observed price	2022-03-13	117
Observed price	2022-03-22	118
Observed price	2022-04-08	123
Observed price	2022-04-17	120
Observed price	2022-05-04	113
Observed price	2022-05-08	108
Observed price	2022-05-30	115
Observed price	2022-06-03	116
Observed price	2022-06-16	103
Observed price	2022-07-04	110
Observed price	2022-07-21	108
Observed price	2022-08-03	109
Observed price	2022-08-12	111
Observed price	2022-08-20	108
Observed price	2022-08-29	102
Observed price	2022-09-15	105
Observed price	2022-09-28	97.3
Observed price	2022-10-16	104
Observed price	2022-10-20	96.2
Observed price	2022-11-07	99.0
Observed price	2022-11-28	107
Observed price	2022-12-03	106
Observed price	2022-12-11	110
Observed price	2022-12-29	109
Observed price	2023-01-11	114
Observed price	2023-01-24	112
Observed price	2023-02-14	107
Observed price	2023-02-19	105
Observed price	2023-03-12	98.3
Observed price	2023-03-25	98.2
Observed price	2023-04-07	104
Observed price	2023-04-12	103
Observed price	2023-05-03	112
Observed price	2023-05-08	111
Observed price	2023-05-29	102
Observed price	2023-06-11	101
Observed price	2023-06-24	108
Observed price	2023-07-07	107
Observed price	2023-07-20	114
Observed price	2023-07-25	114
Observed price	2023-08-15	105
Observed price	2023-08-20	104
Observed price	2023-09-06	101
Observed price	2023-09-15	102
Observed price	2023-10-02	96.0
Observed price	2023-10-15	92.2
Observed price	2023-10-19	95.3
Observed price	2023-11-10	94.6
Observed price	2023-11-23	103
Observed price	2023-12-02	105
Observed price	2023-12-23	109
Observed price	2024-01-01	110
Observed price	2024-01-10	114
Observed price	2024-01-23	113
Observed price	2024-01-31	113
Observed price	2024-02-18	116
Observed price	2024-03-10	120
Observed price	2024-03-15	117
Observed price	2024-04-05	111
Observed price	2024-04-10	112
Observed price	2024-05-01	106
Observed price	2024-05-06	105
Observed price	2024-05-27	102
Observed price	2024-06-01	103
Observed price	2024-06-09	106
Observed price	2024-06-27	104
Observed price	2024-07-18	101
Observed price	2024-07-23	104
Observed price	2024-08-09	109
Observed price	2024-08-18	111
Observed price	2024-09-09	116
Observed price	2024-09-13	117
Observed price	2024-09-26	113
Observed price	2024-10-18	117
Observed price	2024-10-26	115
Observed price	2024-11-13	116
Observed price	2024-11-26	119
Observed price	2024-11-30	117
Observed price	2024-12-17	113
Observed price	2024-12-30	113
Observed price	2025-01-08	114
Observed price	2025-01-21	121
Observed price	2025-02-07	132
Observed price	2025-02-16	132
Observed price	2025-03-05	137
Observed price	2025-03-23	126
Observed price	2025-03-31	132
Observed price	2025-04-09	125
Observed price	2025-05-01	132
Observed price	2025-05-18	135
Observed price	2025-05-22	132
Observed price	2025-05-31	133
Observed price	2025-06-22	135
Observed price	2025-06-26	137
Observed price	2025-07-18	122
Observed price	2025-07-22	126
Observed price	2025-08-08	132
Observed price	2025-08-21	132
Observed price	2025-08-26	132
Observed price	2025-09-12	133
Observed price	2025-09-21	135
Observed price	2025-10-12	133
Observed price	2025-10-30	124
Observed price	2025-11-03	124
Observed price	2025-11-16	130
Observed price	2025-11-29	127
Observed price	2025-12-08	123
Observed price	2026-01-07	127
Observed price	2026-01-16	123
Observed price	2026-01-20	121
Observed price	2026-01-29	106
Observed price	2026-02-24	114
Observed price	2026-03-09	111
Observed price	2026-03-17	108
Observed price	2026-04-04	102
Observed price	2026-04-08	103
Observed price	2026-04-30	90.6
Observed price	2026-05-13	84.1
Observed price	2026-05-17	87.6
Observed price	2026-05-30	87.2
Observed price	2026-06-08	91.2
Observed price	2026-06-30	90.7
Observed price	2026-07-17	101
Observed price	2026-07-21	100
Observed price	2026-08-12	111
Observed price	2026-08-21	117
Observed price	2026-09-07	106
Observed price	2026-09-22	104
Observed price	2026-09-24	101
Observed price	2026-09-25	101
Published advisor forecast	2026-09-18	103
Published advisor forecast	2026-12-18	106
Published advisor forecast	2027-03-18	104
Published advisor forecast	2027-06-18	108
Published advisor forecast	2027-09-18	110
Published advisor forecast	2027-12-18	113
Published advisor forecast	2028-03-18	117
Published advisor forecast	2028-06-18	120
Published advisor forecast	2028-09-18	124
Published advisor forecast	2028-12-18	127
Published advisor forecast	2029-03-18	124
Published advisor forecast	2029-06-18	127
Published advisor forecast	2029-09-18	131
Published advisor forecast	2029-12-18	135
Published advisor forecast	2030-03-18	138
Published advisor forecast	2030-06-18	135
Published advisor forecast	2030-09-18	139
Published advisor forecast	2030-12-18	142
Published advisor forecast	2031-03-18	145
Published advisor forecast	2031-06-18	149
Published advisor forecast	2031-09-18	152

2. Scenarios & Signals

Bull case

The bull case activates when litigation certainty and rate relief arrive together. A global NEC inventory settlement frees the buyback, leverage falls faster than guided, and Cologuard sustains double-digit growth that validates the $23bn enterprise value paid for Exact Sciences. Group holds near 8%, adjusted EPS compounds toward $9 by 2031, and defensive rotation restores a low-20s multiple. Abbott then reprices as a diversified healthcare compounder rather than a levered acquirer, delivering low-to-mid-teens annualised total return.

Bear case

The bear case activates if CGM commoditisation and regulatory escalation collide. Libre growth slides below high single digits under Dexcom and Medtronic pricing pressure while an FDA consent decree interrupts sensor supply; diagnostics comparable growth disappoints, exposing the Exact purchase as scale without economics. Interest on $20bn of debt then consumes the earnings the deal was supposed to add, the NEC tail accretes past $3bn, and the multiple settles permanently near 15x - leaving the shares range-bound with the dividend as the only return.

Current crowd narrative

The consensus treats Abbott as a broken on probation: 27 analysts still rate it Buy with targets near $120-$124, yet the shares sit barely above a 52-week low after a 37% peak-to-trough drawdown [15][17][18]. The anchoring bias is the $139 June 2025 high, which frames every print as disappointment. Priced in: slower CGM, deal indigestion and open litigation.

Alpha-gap assessment

The crowd underestimates these shares, and the mispricing hides in the accounting. The supplied 33x trailing P/E is a GAAP artefact of Exact Sciences amortisation, $20bn of new interest and litigation charges; against guided FY2026 adjusted of $5.45-$5.60, $103 is roughly 18.5x forward [1]. Investors are extrapolating a temporary GAAP distortion into a permanent quality downgrade, while TTM of $8.72bn, a 4.9% FCF yield, keeps compounding untouched by the noise.

Convergence catalyst

The January 2027 FY2027 guidance print is the pivot: the first framework in which Exact has lapped and adjusted reverts to high single digits on a clean base. First observable sign of repricing is guidance above $6.00 with comparable growth held near 7%, drawing target upgrades.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.3
Expected volatility regime: moderate
Convergence-cycle position: stabilization

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Devices AND CGM Compounding Engine	Follow the segment data: Medical Devices grew 8.5% in Q2 2026, electrophysiology low-teens, rhythm management 9.5%, and CGM sales cleared $2bn at +9.5% [1][3]. This is a portfolio of installed-base razor-and-blade franchises with annuity-like consumable revenue, which converts mid-single-digit volume into high-single-digit earnings via fixed-cost absorption. Libre Duo, reimbursement expansion into basal and non-insulin cohorts, and structural-heart pipeline extend the runway well past 2028.	Not available	+18.0%
Defensive Rotation Reclaims Healthcare	The evidence chain is unusual: S&P 500 Health Care was among the weakest 2026 sectors, yet Abbott fell 18.9% over the prior year versus 28.9% for the Medical Products industry [15][16]. Relative resilience during sector capitulation signals franchise quality, not decay. As the 2026-27 tightening cycle matures and cyclical earnings decelerate, mandate-driven flows historically rebuild defensive medtech weightings, restoring multiple points to a de-rated compounder.	Not available	+14.0%
Exact Dilution LAPS Accretion Arrives	Abbott bought Exact Sciences for roughly $21bn equity, closed 23 March 2026, guiding about $0.20 of 2026 adjusted EPS dilution and roughly $3bn of incremental sales [4][5][7]. That dilution is a dated, decaying charge: it laps in 2027, while Cologuard's mid-teens growth and diagnostics scale above $12bn persist. Deleveraging from an initial ~2.7x adjusted gross debt/EBITDA releases interest expense back into earnings from 2028 onward.	Not available	+12.0%
Gross Margin Quietly Ratchets Higher	Adjusted gross margin reached 58.0% of sales in Q2 2026, up 100 basis points year over year, with adjusted R&D at 6.9% and SG&A at 28.6% [3]. Mix is doing the work: higher-margin devices and cancer diagnostics displace lower-margin nutrition and respiratory testing. FY2025 free cash flow of $7.39bn on 16.7% FCF margin, and $8.72bn TTM, show the conversion is cash, not accrual cosmetics.	Not available	+9.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
FIVE Percent Discount RATE TAX	The decisive fact is not company-specific: the US 10-year closed at 4.998% on 18 September 2026 after the Fed took the range to 3.75%-4.00%. Long-duration defensive equities with 2.4% yields compete directly with risk-free paper, and Abbott's terminal-value-heavy cash flows discount harshly. Fed medians point to 4.1% year-end 2026 and 2027, so this drag persists through at least 2028 before easing.	Not available	-13.0%
Cgm's Shrinking Growth Premium	Trace the deceleration: FreeStyle Libre grew 17% in FY2025 on roughly $7.6bn of sales, then $2.08bn at +13.8% in Q1 2026, then above $2bn at +9.5% in Q2 [8][14][3]. Dexcom and Medtronic are pressing hard in a market moving toward commoditised sensors and pharmacy-channel price erosion [21]. Each point of CGM growth lost costs both earnings and the growth multiple investors assign the whole Diabetes Care franchise.	Not available	-11.0%
THE NEC TAIL Nobody HAS Sized	Abbott resolved Gill plus roughly 2,000 infants' claims for about $670m on 20 August 2026, expressly without admitting liability, yet disclosed roughly 1,700 suits covering approximately 12,700 individual infants still pending [9][10][11]. That is a partial inventory settlement, not a global MDL-3026 resolution. A defensible $1.5-3bn residual accrual over the horizon caps buyback capacity and keeps a headline-risk discount embedded in the multiple until an inventory-wide deal lands.	Not available	-8.0%
Twenty Billion OF Expensive Leverage	The Exact purchase was funded largely by a reported $20bn senior notes offering with coupons ranging from roughly 3.7% to 6.0% [8]; tranche detail is single-source and unverified. Interest plus purchase-price amortisation is why Q2 2026 GAAP net income fell 47.8% on 13% reported revenue growth. Until leverage falls from about 2.7x, buybacks stay subordinated to debt paydown, muting per-share compounding through 2028.	Not available	-7.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Cancer Screening Becomes THE Second Libre	If Cologuard's mid-teens growth broadens into blood-based colorectal and multi-cancer screening with Medicare coverage and guideline inclusion, Abbott's diagnostics franchise re-rates from a commodity testing business to a secular growth asset. Watch 2028-2030 for evidence: diagnostics comparable growth sustaining above 8% would validate the $23bn enterprise value paid. That would lift group organic growth toward 8-9% and justify a low-20s forward multiple rather than today's 18.5x. It remains under 50% because reimbursement timelines, competing liquid-biopsy entrants and screening adherence economics are all unsettled.	29.0%	+22.0%
Global NEC Settlement Clears THE Docket	A comprehensive inventory resolution covering the remaining ~12,700 infant claims, plausibly negotiated during 2027-2028 once further bellwethers are tried, would convert an unquantified legal tail into a dated, financed charge [10][11]. Abbott has won the first three bellwethers on summary judgment, which strengthens its per-claim bargaining position below the $335k implied by the August 2026 deal [12]. Removing binary litigation risk typically restores one to two turns of forward multiple. It stays below 50% because plaintiff firms holding weaker inventories have little incentive to settle cheaply.	34.0%	+14.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Libre Recall Escalates TO Consent Decree	Secondary reporting links a manufacturing defect in certain FreeStyle Libre 3 sensors to approximately 860 serious injuries and seven deaths as of 7 January 2026, with a Class I recall and a warning letter citing facility deficiencies [19][20]; this is unverified against FDA databases. Escalation into a consent decree or extended production suspension during 2027-2028 would strike Abbott's single largest growth franchise, roughly $7.6bn of annual sales, damaging both earnings and the quality premium. Probability stays low because Abbott states the root cause was identified and resolved.	19.0%	-24.0%
Policy Shock Meets Guidance CUT	A combination of US drug- and device-pricing intervention, extension of Section 301-style tariffs to medtech inputs, and deeper China volume-based procurement cuts would compress Abbott's Established Pharmaceuticals and Diagnostics economics simultaneously. If that coincided with a 2027-2028 guidance reset below 6% comparable growth, the market would reprice Abbott as a low-growth industrial at 15x rather than a compounder at 19x. It stays below 50% because Abbott's geographic and segment diversification historically absorbs single-jurisdiction shocks better than pure-play peers.	28.0%	-19.0%

Step-by-step forecast path

Universal Investor forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_3a0e112c-4d8a-52c6-bea1-a405e3ac70e7__sb7__20260920064920277661
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	December 18, 2026	+3.0%	105.69	The 21 October Q3 print lands inside the $1.38-$1.46 adjusted guide, confirming the raised full-year range. Modest relief rally from a de-rated base, capped by a 5% ten-year yield.
2	March 18, 2027	-2.0%	103.57	January FY2027 guidance arrives with conservative framing as Exact integration costs persist and NEC accrual disclosure expands. Sector remains out of favour; profit-taking trims the autumn recovery.
3	June 18, 2027	+4.0%	107.72	Exact dilution laps against the March 2026 close, and Q1 2027 delivers the first clean comparable-growth quarter. Adjusted EPS momentum reasserts itself and analyst targets near $124 regain credibility.
4	September 18, 2027	+2.0%	109.87	Mid-year consolidation. CGM growth stabilises near 9-10% as Libre Duo rollout offsets Dexcom pricing pressure, while a still-restrictive Fed caps multiple expansion for defensive yield names.
5	December 18, 2027	+3.0%	113.17	Deleveraging progress toward 2.3x becomes visible, restoring buyback capacity. Additional NEC bellwether outcomes favouring Abbott reduce the litigation discount embedded since the August 2026 partial settlement.
6	March 18, 2028	+3.0%	116.56	FY2028 guidance for high-single-digit adjusted EPS growth on a clean base validates the compounder thesis. Diagnostics comparable growth approaching 7% shows the Exact acquisition earning its cost of capital.
7	June 18, 2028	+3.0%	120.06	An easing rate path lifts long-duration defensive valuations. Abbott's adjusted gross margin holding near 59% on device and cancer-screening mix supports gradual multiple repair toward 19x forward.
8	September 18, 2028	+3.0%	123.66	Electrophysiology and structural heart continue high-single-digit expansion despite competitive intensity in mitral. Free cash flow above $10bn funds both the 56th consecutive dividend increase and resumed repurchases.
9	December 18, 2028	+3.0%	127.37	Purchase-price amortisation from Exact begins rolling off, narrowing the GAAP-to-adjusted gap. Investors recognising improved reported earnings quality bid the multiple modestly higher into year-end.
10	March 18, 2029	-3.0%	123.55	A cyclical setback: US healthcare pricing policy noise plus a soft respiratory testing season pressure Diagnostics. Guidance is trimmed at the margin and defensive medtech gives back recent gains.
11	June 18, 2029	+3.0%	127.26	Recovery as the policy scare fades without legislated price cuts. Cologuard and blood-based screening adoption data support the diagnostics growth algorithm, restoring confidence in the 7-8% segment framework.
12	September 18, 2029	+3.0%	131.07	Leverage reaches roughly 2x and management signals a larger repurchase authorisation. Per-share compounding accelerates as share count shrinks against steady high-single-digit operating earnings growth.
13	December 18, 2029	+3.0%	135.01	Litigation inventory materially cleared through staged settlements, removing the headline-risk discount. Abbott trades closer to large-cap medtech peers on forward adjusted earnings rather than at a persistent discount.
14	March 18, 2030	+2.0%	137.71	FY2030 guidance confirms the roughly 7% sustainable growth algorithm across Nutrition, Diagnostics, EPD and Devices. Steady rather than spectacular; the multiple is already partially repaired.
15	June 18, 2030	-2.0%	134.95	CGM price erosion intensifies as sensor competition broadens and payers consolidate contracts. Diabetes Care growth slips to mid-single digits, prompting a modest de-rating of the franchise premium.
16	September 18, 2030	+3.0%	139.00	Next-generation sensing and expanded non-insulin reimbursement stabilise Diabetes Care volumes. Devices and cancer screening carry group growth, and cash conversion above 18% of revenue reassures income investors.
17	December 18, 2030	+2.0%	141.78	Mature-phase compounding: adjusted EPS near $7.50, dividend raised for a 58th consecutive year. Returns increasingly reflect earnings growth rather than further multiple expansion.
18	March 18, 2031	+2.0%	144.62	Balance-sheet capacity restored, enabling optional bolt-on diagnostics or device acquisitions. Market rewards disciplined capital allocation modestly, mindful of the 2026 Exact integration experience.
19	June 18, 2031	+3.0%	148.96	Emerging-market Established Pharmaceuticals growth of 8-9% plus device share gains sustain the algorithm. A normalised rate environment supports a stable high-teens forward multiple on rising earnings.
20	September 18, 2031	+2.0%	151.93	Horizon exit near $152, roughly 19x projected adjusted EPS of about $8.00. Returns arrive as earnings compounding plus dividends, with the 2026 de-rating largely but not fully reversed.

Advisor and configuration

Advisor: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release
Persona: Universal Investor
Archetype: The Polymath
Model: 2026-07-24 release
Provider: Anthropic
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Universal Investor advisor methodology

Configuration components

aiassmprmtcmpnt_b995bbe2-6a15-55be-a576-525904f696e8
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_930157b1-05d7-5699-bf0a-738645ee42fd
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Research sources

[1]Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance - Jul 16, 2026abbott.mediaroom.com
[2]Abbott Laboratories (ABT) Q2 2026 Earnings Report - Results, Call & Slides - TipRanks.comtipranks.com
[3]Abbott Laboratories (ABT) Q2 2026 Earnings Call Highlights: Strong Growth in Key Segments and Raised EPS Guidancegurufocus.com
[4]Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segmentsprnewswire.com
[5]Abbott acquisition of Exact Sciences set to close on March 23, 2026 - Mar 20, 2026abbott.mediaroom.com
[6]Abbott completes $21 billion acquisition of Exact Sciences, delisting EXAS from Nasdaq By Investing.cominvesting.com
[7]Acquisition of Exact Sciences 20 | November | 2025abbottinvestor.com
[8]Abbott Stock Sits 26% Off Its Peak While Analysts Back a $132 Mean Price Targettikr.com
[9]ABBOTT LABORATORIES - Form 8-K - FY2026sec.gov
[10]NEC Baby Formula Lawsuits Continue After Abbott Settlementlegalexaminer.com
[11]Abbott to Pay $670 Million to Settle About 2,000 NEC Formula Cases (MDL-3026) | MDL Updatemdlupdate.com
[12]NEC Baby Formula Lawsuit September 2026 | $670M Abbott Settlementconsumernotice.org
[13]Abbott Price Prediction: Where Will the Stock Be in 2027 - 24/7 Wall St.247wallst.com
[14]Wall Street Refuses to Blink: 2 Healthcare Stocks at 52-Week Lows That Analysts Still Love - 24/7 Wall St.247wallst.com
[15]Abbott Stock Is Trading at 52-Week Lows but Insiders Are Gobbling Up Shares of This Blue-Chip Dividend Payerfinance.yahoo.com
[16]Abbott Laboratories stock gains as Citi lifts price target and guidance stays firmad-hoc-news.de
[17]Abbott Laboratories (ABT) Stock Forecast & Analyst Price Targetsstockanalysis.com
[18]Abbott Laboratories (ABT) Stock Forecast, Price Targets and Analysts Predictions - TipRanks.comtipranks.com
[19]Why Is Abbott Stock Trending Lower?finance.yahoo.com
[20]Abbott Laboratories Stock Is Down 16% From Its 52-Week High. Here’s Where the Stock Could Go in 2026tikr.com
[21]Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy - 24/7 Wall St.247wallst.com
[22]Abbott Laboratories Earnings - Analysis & Highlights for Q2 2026alpha-sense.com
[23]Abbott Laboratories (ABT) Stock Price, News, Quote & History - Yahoo Financefinance.yahoo.com

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Superintelligence — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.8 Flash

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.